Incyte (INCY) Cash from Restructuring (2010 - 2011)
Incyte posted quarterly Cash from Restructuring of -$108000.0 for Q4 2011, down 640.0% year-on-year from $20000.0 in Q4 2010, and down 183.72% on a QoQ basis from $129000.0 in Q2 2011.
Incyte (INCY) has 2 years of Cash from Restructuring data on file, last reported at -$108000.0 in Q4 2011.
- For the quarter ending Q4 2011, Cash from Restructuring fell 640.0% year-over-year to -$108000.0; the trailing twelve-month figure through Dec 2011 stood at -$88000.0 (up 76.78% YoY), and the FY2011 full-year result was -$88000.0, up 76.78% from the prior year.
- Cash from Restructuring for Q4 2011 stood at -$108000.0, down from $129000.0 in the prior quarter.
- Across five years, Cash from Restructuring topped out at $129000.0 in Q2 2011 and bottomed at -$145000.0 in Q2 2010.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Incyte | 19.28 Bn | 15.27 Bn | 1.17 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2011 | -108,000.00 |
| Jun 30, 2011 | 129,000.00 |
| Mar 31, 2011 | -109,000.00 |
| Dec 31, 2010 | 20,000.00 |
| Sep 30, 2010 | -139,000.00 |
| Jun 30, 2010 | -145,000.00 |
| Mar 31, 2010 | -115,000.00 |